NCT05052255View on ClinicalTrials.gov

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

RVU120

RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.

Trial Locations (7)

28223

Next Oncology Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón

Unknown

Beskidzkie Centrum Onkologii, Szpital Miejski im., Bielsko-Biala

80-214

Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz, Gdansk

40-514

UCK im. prof. K. Gibińskiego, Katowice

02-781

Maria Sklodowska-Curie National Research Institute of Oncology / Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warsaw

08023

Next Oncology Hospital Quironsalud Barcelona, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Ryvu Therapeutics SA

INDUSTRY